(Q35162494)

6 August 2017

Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials (English)

1 reference

6 August 2017

0 references

1 reference

Christopher G Willett

1

1 reference

6 August 2017

Howard Safran

2

1 reference

6 August 2017

Ross A Abrams

3

1 reference

6 August 2017

William F Regine

4

1 reference

6 August 2017

Tyvin A Rich

5

1 reference

6 August 2017

Gastrointestinal Committee of the Radiation Therapy Oncology Group

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

6 August 2017

1 reference

6 August 2017

56

1 reference

6 August 2017

31-37

1 reference

6 August 2017

4 Suppl

1 reference

6 August 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Current management of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Investigation of taxol as a potential radiation sensitizer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Paclitaxel and concurrent radiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Function and regulation of ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Adjuvant therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Cancer of the pancreas. 50 years of surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12 year period

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

High dose, external beam and intraoperative radiotherapy in the treatment of resectable and unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Should pancreaticoduodenectomy be performed in octogenarians?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900446-2

7 January 2021

10.1016/S0360-3016(03)00446-2

Identifiers

DOI

1 reference

6 August 2017

1 reference